{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"34"}]}],"title":"Overall confirmed ADA+"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"27"}]}],"title":"Overall ADA-"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"61"}],"units":"Participants"}],"description":"Blood samples were collected for immunogenicity analysis. Anti-drug antibody positive (ADA+) participants were those with a positive result on the first test and also a positive result on the confirmatory test. Anti-drug antibody negative (ADA-) participants had a negative result on the first test.","groups":[{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks based on available data from the Phase 1 (JZP458-101) healthy volunteer study.","id":"OG000","title":"Part A: JZP-458 IM 25 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 37.5 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG001","title":"Part A: JZP-458 IM 37.5 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG002","title":"Part A: JZP-458 IM 25 (MW)/50 mg/m^2 (F)"},{"description":"Participants who received an intravenous (IV) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG003","title":"Part B: JZP-458 IV 25 (MW)/50 mg/m^2 (F)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity was assessed in the Safety Analysis Set.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 days (ADA- samples) after last dose of last course and up to 6 months (ADA+ samples) after last dose of last course, up to approximately 2 years 7 months","title":"Number of Participants Who Are Anti-drug Antibody Positive or Negative Against JZP-458","type":"SECONDARY","unitOfMeasure":"Participants"}